University of Oklahoma Awarded $2.9 Million NCI Grant for Opaganib Clinical Trial

Article summary

The National Cancer Institute has awarded a $2.9 million grant to the University of Oklahoma to fund Phase 1b/2 clinical trials evaluating RedHill Biopharma's opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma.